New oral medications for treating progressive lung scarring
Novel oral small molecules for progressive pulmonary fibrosis
This study is testing a new oral medication for people with idiopathic pulmonary fibrosis (IPF) that aims to slow down or even reverse lung damage by targeting cells that cause scarring, offering a safer and more effective option than current treatments.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Novomedix, INC. NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project ID | NIH-11008167 on NIH RePORTER |
What this research studies
This research focuses on developing a new type of oral medication aimed at treating idiopathic pulmonary fibrosis (IPF), a serious lung disease that leads to progressive scarring of lung tissue. The approach involves creating small molecules that can inhibit the activation of myofibroblasts, which are responsible for excessive collagen production in the lungs. By targeting these cells, the treatment aims to not only slow down the progression of the disease but potentially reverse some of the damage caused by fibrosis. The research is being conducted by NovoMedix, Inc. in San Diego, and it seeks to provide a safer and more effective alternative to existing therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis or other forms of progressive pulmonary fibrosis.
Not a fit: Patients with non-progressive lung diseases or those who do not have a diagnosis of pulmonary fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that significantly improves the quality of life and survival rates for patients with idiopathic pulmonary fibrosis.
How similar studies have performed: Previous research has shown promise in targeting myofibroblast activation for treating fibrosis, indicating that this approach may be viable.
Where this research is happening
San Diego, United States
- Novomedix, INC. — San Diego, United States (Active)
Researchers
- Principal investigator: Swindlehurst, Cathy a — Novomedix, INC.
- Study coordinator: Swindlehurst, Cathy a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.